Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

STRATA Skin Sciences (SSKN) Other financing activities (2018 - 2023)

STRATA Skin Sciences' Other financing activities history spans 6 years, with the latest figure at $62000.0 for Q3 2023.

On a quarterly basis, Other financing activities changed N/A to $62000.0 in Q3 2023 year-over-year; TTM through Dec 2024 was $62000.0, a 0.0% change, with the full-year FY2023 number at $97000.0, changed N/A from a year prior.
Other financing activities hit $62000.0 in Q3 2023 for STRATA Skin Sciences, down from $2.3 million in the prior quarter.
Over the last five years, Other financing activities for SSKN hit a ceiling of $62000.0 in Q3 2023 and a floor of $62000.0 in Q3 2023.